Brokerages Set Alexion Pharmaceuticals, Inc. (ALXN) PT at $158.62

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has received a consensus recommendation of “Buy” from the twenty-six research firms that are currently covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $158.62.

Several research analysts have recently commented on ALXN shares. Stifel Nicolaus reissued a “buy” rating and issued a $157.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. Jefferies Group LLC set a $120.00 target price on Alexion Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, June 8th. Royal Bank Of Canada reissued an “outperform” rating and issued a $177.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, March 27th. Barclays PLC reissued an “overweight” rating and issued a $155.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 14th.

Shares of Alexion Pharmaceuticals (ALXN) traded down 0.18% during mid-day trading on Friday, hitting $125.84. The company had a trading volume of 1,203,003 shares. The firm’s 50 day moving average is $112.77 and its 200-day moving average is $122.35. The firm has a market cap of $28.26 billion, a PE ratio of 59.95 and a beta of 1.45. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $145.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.33. The company had revenue of $870 million for the quarter, compared to the consensus estimate of $826.63 million. Alexion Pharmaceuticals had a return on equity of 11.72% and a net margin of 14.52%. The company’s quarterly revenue was up 24.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.11 earnings per share. On average, equities analysts expect that Alexion Pharmaceuticals will post $5.31 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by sleekmoney and is owned by of sleekmoney. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://sleekmoney.com/brokerages-set-alexion-pharmaceuticals-inc-alxn-pt-at-158-62/1941430.html.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson acquired 10,000 shares of Alexion Pharmaceuticals stock in a transaction dated Wednesday, June 14th. The stock was bought at an average cost of $116.72 per share, for a total transaction of $1,167,200.00. Following the purchase, the chief executive officer now directly owns 38,725 shares in the company, valued at approximately $4,519,982. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of Alexion Pharmaceuticals stock in a transaction dated Wednesday, June 14th. The shares were acquired at an average price of $116.32 per share, with a total value of $156,910,445.60. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 2,019,734 shares of company stock valued at $235,606,846. Company insiders own 4.35% of the company’s stock.

A number of large investors have recently modified their holdings of ALXN. Russell Investments Group Ltd. purchased a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $3,024,000. Private Advisor Group LLC purchased a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $231,000. Dimensional Fund Advisors LP increased its stake in shares of Alexion Pharmaceuticals by 0.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 307,780 shares of the biopharmaceutical company’s stock valued at $37,660,000 after buying an additional 1,385 shares during the period. Credit Agricole S A increased its stake in shares of Alexion Pharmaceuticals by 24.7% in the fourth quarter. Credit Agricole S A now owns 62,642 shares of the biopharmaceutical company’s stock valued at $7,665,000 after buying an additional 12,410 shares during the period. Finally, Flinton Capital Management LLC purchased a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $562,000. Institutional investors and hedge funds own 94.14% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/brokerages-set-alexion-pharmaceuticals-inc-alxn-pt-at-158-62/1941430.html

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *